The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a third more sales per ad dollar.

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...

A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...